152 results
Page 5 of 8
8-K
9ut4c3g9
2 Dec 20
Intellia Therapeutics Announces Proposed Public Offering of Common Stock
4:59pm
8-K
EX-99.1
vrvaksl 0bkcn
2 Dec 20
Intellia Therapeutics Announces Proposed Public Offering of Common Stock
4:59pm
8-K
EX-1.1
sjb7w3n 7w
2 Dec 20
Intellia Therapeutics Announces Proposed Public Offering of Common Stock
4:59pm
424B5
tju5ms
2 Dec 20
Prospectus supplement for primary offering
4:00pm
424B5
cgfcre
30 Nov 20
Prospectus supplement for primary offering
5:06pm
8-K
EX-99.1
pcrqa jgdxps4l
9 Nov 20
Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis
7:54am
8-K
EX-99.1
lmxi81ccdlisrud6yn
5 Nov 20
Intellia Therapeutics Announces Third Quarter 2020 Financial Results
7:56am
8-K
EX-99.1
cjanp
19 Oct 20
Intellia Therapeutics Receives Authorization to Initiate Phase 1
8:05am
8-K
EX-99.1
snxfrih
5 Oct 20
Intellia Therapeutics Names John F. Crowley to Board of Directors
7:45am
8-K
EX-99.1
sv7gyw5iyo
6 Aug 20
Intellia Therapeutics Announces Second Quarter 2020 Financial Results
7:45am
8-K
EX-99.2
rq8s m1ckpib7jl
3 Jun 20
Intellia Therapeutics Announces Proposed Public Offering of Common Stock
5:21pm
8-K
4xipa 9p5tph
3 Jun 20
Intellia Therapeutics Announces Proposed Public Offering of Common Stock
5:21pm
8-K
EX-99.1
6a5fxn
3 Jun 20
Intellia Therapeutics Announces Proposed Public Offering of Common Stock
5:21pm
8-K
EX-1.1
1lf0a 988yt
3 Jun 20
Intellia Therapeutics Announces Proposed Public Offering of Common Stock
5:21pm
424B5
a43wmi im
3 Jun 20
Prospectus supplement for primary offering
5:14pm
424B5
de9 3ybm3ii
1 Jun 20
Prospectus supplement for primary offering
4:52pm
8-K
EX-10.2
ypwy4 futf2a4ymug
1 Jun 20
Entry into a Material Definitive Agreement
7:13am
8-K
EX-10.1
2iac8niu6jrej7zdpo6
1 Jun 20
Entry into a Material Definitive Agreement
7:13am